# A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

> **NCT03268083** · PHASE2 · COMPLETED · sponsor: **Enimmune Corporation** · enrollment: 140 (actual)

## Conditions studied

- Enterovirus Infections

## Interventions

- **BIOLOGICAL:** EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
- **BIOLOGICAL:** EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
- **BIOLOGICAL:** EV71 vaccine ([1 μg total protein ] per dose)

## Key facts

- **NCT ID:** NCT03268083
- **Lead sponsor:** Enimmune Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03268083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03268083, "A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03268083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*